Pereira MP, Steinke S, Zeidler C, Forner C, Riepe C, Augustin M, et al. European academy of dermatology and venereology European prurigo project: expert consensus on the definition, classification and terminology of chronic prurigo. J Eur Acad Dermatol Venereol. 2018;32(7):1059–65. https://doi.org/10.1111/jdv.14570.

Article  CAS  PubMed  Google Scholar 

Huang AH, Williams KA, Kwatra SG. Prurigo nodularis: epidemiology and clinical features. J Am Acad Dermatol. 2020;83(6):1559–65. https://doi.org/10.1016/j.jaad.2020.04.183.

Article  PubMed  Google Scholar 

Elmariah S, Kim B, Berger T, Chisolm S, Kwatra SG, Mollanazar N, et al. Practical approaches for diagnosis and management of prurigo nodularis: United States expert panel consensus. J Am Acad Dermatol. 2021;84(3):747–60. https://doi.org/10.1016/j.jaad.2020.07.025.

Article  PubMed  Google Scholar 

Wikstrom K, Verkko H, Sinikumpu SP, Jokelainen J, Tasanen K, Huilaja L. Comorbidities of prurigo nodularis in Finland between 1996 and 2019. Acta Derm Venereol. 2021;101(7):adv00508. https://doi.org/10.2340/00015555-3872.

Article  PubMed  Google Scholar 

Iking A, Grundmann S, Chatzigeorgakidis E, Phan NQ, Klein D, Ständer S. Prurigo as a symptom of atopic and non-atopic diseases: aetiological survey in a consecutive cohort of 108 patients. J Eur Acad Dermatol Venereol. 2013;27(5):550–7. https://doi.org/10.1111/j.1468-3083.2012.04481.x.

Article  CAS  PubMed  Google Scholar 

Hamilton JD, Harel S, Swanson BN, Brian W, Chen Z, Rice MS, et al. Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases. Clin Exp Allergy. 2021;51(7):915–31. https://doi.org/10.1111/cea.13954.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee HJ, Yang E-A, Chun YH, Kim HH, Kim HS. Blood eosinophil counts as a biomarker for allergen sensitization in childhood allergic diseases in comparison with total IgE. Allergy Asthma Respir Dis. 2024;12(1):26–30. https://doi.org/10.4168/aard.2024.12.1.26.

Article  Google Scholar 

Nagata M, Nakagome K, Soma T. Mechanisms of eosinophilic inflammation. Asia Pac Allergy. 2020;10(2):e14. https://doi.org/10.5415/apallergy.2020.10.e14.

Article  PubMed  PubMed Central  Google Scholar 

Aggarwal P, Choi J, Sutaria N, Roh YS, Wongvibulsin S, Williams KA, et al. Clinical characteristics and disease burden in prurigo nodularis. Clin Exp Dermatol. 2021;46(7):1277–84. https://doi.org/10.1111/ced.14722.

Article  CAS  PubMed  Google Scholar 

Huang AH, Canner JK, Khanna R, Kang S, Kwatra SG. Real-world prevalence of prurigo nodularis and burden of associated diseases. J Investig Dermatol. 2020;140(2):480-3.e4. https://doi.org/10.1016/j.jid.2019.07.697.

Article  CAS  PubMed  Google Scholar 

Tanaka M, Aiba S, Matsumura N, Aoyama H, Tagami H. Prurigo nodularis consists of two distinct forms: early-onset atopic and late-onset non-atopic. Dermatology. 1995;190(4):269–76. https://doi.org/10.1159/000246715.

Article  CAS  PubMed  Google Scholar 

US Food and Drug Administration. Dupixent: prescribing information. 2023. https://www.regeneron.com/downloads/dupixent_fpi.pdf. Accessed 26 May 2025.

European Medicines Agency. Dupixent: summary of product characteristics. 2023. https://www.ema.europa.eu/en/documents/product-information/dupixent-epar-product-information_en.pdf. Accessed 26 May 2025.

Sanofi. Dupixent. Press release: Dupixent® (dupilumab) receives additional approval for the treatment of prurigo nodularis in Japan. June 26, 2023. https://www.sanofi.co.jp/assets/dot-jp/pressreleases/2023/230626.pdf. Accessed 26 May 2025.

Beck LA, Thaçi D, Hamilton JD, Graham NM, Bieber T, Rocklin R, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371(2):130–9. https://doi.org/10.1056/NEJMoa1314768.

Article  CAS  PubMed  Google Scholar 

Yosipovitch G, Mollanazar N, Ständer S, Kwatra SG, Kim BS, Laws E, et al. Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials. Nat Med. 2023;29(5):1180–90. https://doi.org/10.1038/s41591-023-02320-9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Oetjen LK, Mack MR, Feng J, Whelan TM, Niu H, Guo CJ, et al. Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch. Cell. 2017;171(1):217-28.e13. https://doi.org/10.1016/j.cell.2017.08.006.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335–48. https://doi.org/10.1056/NEJMoa1610020.

Article  CAS  PubMed  Google Scholar 

Bachert C, Han JK, Desrosiers M, Hellings PW, Amin N, Lee SE, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019;394(10209):1638–50. https://doi.org/10.1016/S0140-6736(19)31881-1.

Article  CAS  PubMed  Google Scholar 

Dellon ES, Rothenberg ME, Collins MH, Hirano I, Chehade M, Bredenoord AJ, et al. Dupilumab in adults and adolescents with eosinophilic esophagitis. N Engl J Med. 2022;387(25):2317–30. https://doi.org/10.1056/NEJMoa2205982.

Article  CAS  PubMed  Google Scholar 

Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486–96. https://doi.org/10.1056/NEJMoa1804092.

Article  CAS  PubMed  Google Scholar 

Sanofi. Dupixent. Press release: Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study. September 11, 2024. https://www.sanofi.com/en/media-room/press-releases/2024/2024-09-11-05-00-00-2944237. Accessed 26 May 2025.

Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF, Cole J, Bafadhel M, et al. Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts. N Engl J Med. 2023;389(3):205–14. https://doi.org/10.1056/NEJMoa2303951.

Article  CAS  PubMed  Google Scholar 

Sun CY, Tesfaigzi Y, Lee GY, Chen YH, Weiss ST, Ma KS. Clinical effectiveness and safety of dupilumab in patients with chronic obstructive pulmonary disease: A 7-year population-based cohort study. J Allergy Clin Immun. 2025;155(1):219–22. https://doi.org/10.1016/j.jaci.2024.09.019.

Article  CAS  PubMed  Google Scholar 

Maurer M, Casale TB, Saini SS, Ben-Shoshan M, Giménez-Arnau AM, Bernstein JA, et al. Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): two randomized, double-blind, placebo-controlled, phase 3 trials. J Allergy Clin Immunol. 2024;154(1):184–94. https://doi.org/10.1016/j.jaci.2024.01.028.

Article  CAS  PubMed  Google Scholar 

Ständer S, Zeidler C, Pereira M, Szepietowski JC, McLeod L, Qin S, et al. Worst itch numerical rating scale for prurigo nodularis: a psychometric evaluation. J Eur Acad Dermatol Venereol. 2022;36(4):573–81. https://doi.org/10.1111/jdv.17870.

Article  PubMed  Google Scholar 

Kimel M, Zeidler C, Kwon P, Revicki D, Ständer S. Validation of psychometric properties of the itch numeric rating scale for pruritus associated with prurigo nodularis: a secondary analysis of a randomized clinical trial. JAMA Dermatol. 2020;156(12):1354–8. https://doi.org/10.1001/jamadermatol.2020.3071.

Article  PubMed  Google Scholar 

Riepe C, Osada N, Reich A, Augustin M, Zeidler C, Ständer S. Minimal clinically important difference in chronic pruritus appears to be dependent on baseline itch severity. Acta Derm Venereol. 2019;99(13):1288–90. https://doi.org/10.2340/00015555-3332.

Article  PubMed  Google Scholar 

Ständer HF, Elmariah S, Zeidler C, Spellman M, Ständer S. Diagnostic and treatment algorithm for chronic nodular prurigo. J Am Acad Dermatol. 2020;82(2):460–8. https://doi.org/10.1016/j.jaad.2019.07.022.

Article  PubMed  Google Scholar 

Zeidler C, Pereira MP, Augustin M, Spellman M, Ständer S. Investigator’s global assessment of chronic prurigo: a new instrument for use in clinical trials. Acta Derm Venereol. 2021;101(2):adv00401. https://doi.org/10.2340/00015555-3701.

Article  PubMed  Google Scholar 

Finlay AY, Khan GK. Dermatology life quality index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–6. https://doi.org/10.1111/j.1365-2230.1994.tb01167.x.

Article